How would you approach a patient with localized breast cancer who had a low Oncotype Dx recurrence score but a 20% risk of distant recurrence (without chemotherapy)?

The question asks how to treat a patient with a low Oncotype Dx score, but an estimated risk of recurrence of 20% without chemotherapy.

I am presuming the estimated recurrence risk is based on clinical parameters, such as tumor size and grade, independently from the molecular profiling data. If this...